JP5010281B2 - Ｅｐｃａｍに対する二重特異性抗体を含む薬学的組成物 - Google Patents
Ｅｐｃａｍに対する二重特異性抗体を含む薬学的組成物 Download PDFInfo
- Publication number
- JP5010281B2 JP5010281B2 JP2006529930A JP2006529930A JP5010281B2 JP 5010281 B2 JP5010281 B2 JP 5010281B2 JP 2006529930 A JP2006529930 A JP 2006529930A JP 2006529930 A JP2006529930 A JP 2006529930A JP 5010281 B2 JP5010281 B2 JP 5010281B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- epcam
- acid sequence
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 59
- 102000012804 EPCAM Human genes 0.000 title 1
- 101150084967 EPCAM gene Proteins 0.000 title 1
- 101150057140 TACSTD1 gene Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical group 0.000 claims description 72
- 239000013598 vector Substances 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 39
- 230000014509 gene expression Effects 0.000 claims description 37
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 36
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 35
- 201000010099 disease Diseases 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 230000001613 neoplastic effect Effects 0.000 claims description 18
- 125000003729 nucleotide group Chemical group 0.000 claims description 18
- 239000002773 nucleotide Substances 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 230000002265 prevention Effects 0.000 claims description 14
- 201000009030 Carcinoma Diseases 0.000 claims description 11
- 239000013604 expression vector Substances 0.000 claims description 11
- 230000001105 regulatory effect Effects 0.000 claims description 11
- 230000004913 activation Effects 0.000 claims description 8
- 239000012642 immune effector Substances 0.000 claims description 7
- 229940121354 immunomodulator Drugs 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 208000007660 Residual Neoplasm Diseases 0.000 claims description 6
- 230000002068 genetic effect Effects 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 3
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 118
- 210000004027 cell Anatomy 0.000 description 116
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 108
- 230000027455 binding Effects 0.000 description 72
- 108090000623 proteins and genes Proteins 0.000 description 58
- 239000000427 antigen Substances 0.000 description 46
- 102000036639 antigens Human genes 0.000 description 46
- 108091007433 antigens Proteins 0.000 description 46
- 108090000765 processed proteins & peptides Proteins 0.000 description 44
- 102000004169 proteins and genes Human genes 0.000 description 44
- 102000039446 nucleic acids Human genes 0.000 description 43
- 108020004707 nucleic acids Proteins 0.000 description 43
- 150000001413 amino acids Chemical class 0.000 description 41
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 40
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 40
- 239000012634 fragment Substances 0.000 description 36
- 102000004196 processed proteins & peptides Human genes 0.000 description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 25
- 206010028980 Neoplasm Diseases 0.000 description 23
- 229920001184 polypeptide Polymers 0.000 description 19
- 230000000875 corresponding effect Effects 0.000 description 16
- 108091033319 polynucleotide Proteins 0.000 description 16
- 239000002157 polynucleotide Substances 0.000 description 16
- 102000040430 polynucleotide Human genes 0.000 description 16
- 210000004881 tumor cell Anatomy 0.000 description 15
- 201000011510 cancer Diseases 0.000 description 14
- 238000009396 hybridization Methods 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 210000001744 T-lymphocyte Anatomy 0.000 description 13
- 238000010367 cloning Methods 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 230000001472 cytotoxic effect Effects 0.000 description 12
- 238000010494 dissociation reaction Methods 0.000 description 12
- 230000005593 dissociations Effects 0.000 description 12
- 210000004899 c-terminal region Anatomy 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 230000003993 interaction Effects 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- 108091026890 Coding region Proteins 0.000 description 10
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 10
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 10
- 239000011543 agarose gel Substances 0.000 description 10
- 239000012894 fetal calf serum Substances 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 description 9
- 230000003321 amplification Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 238000001597 immobilized metal affinity chromatography Methods 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 8
- 230000009831 antigen interaction Effects 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 238000010276 construction Methods 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 231100000263 cytotoxicity test Toxicity 0.000 description 7
- 239000012636 effector Substances 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000000137 annealing Methods 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000013599 cloning vector Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 5
- 238000001712 DNA sequencing Methods 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 238000005277 cation exchange chromatography Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
- 238000011260 co-administration Methods 0.000 description 5
- 238000002784 cytotoxicity assay Methods 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 238000002523 gelfiltration Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 101710182846 Polyhedrin Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- -1 aromatic amino acid Chemical group 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000005754 cellular signaling Effects 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 238000001476 gene delivery Methods 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 101150074155 DHFR gene Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 239000012541 Fractogel® Substances 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 239000007987 MES buffer Substances 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 2
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 241000255985 Trichoplusia Species 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 208000037844 advanced solid tumor Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 108020001096 dihydrofolate reductase Proteins 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229960001776 edrecolomab Drugs 0.000 description 2
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 208000037843 metastatic solid tumor Diseases 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 231100000617 superantigen Toxicity 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- CXNPLSGKWMLZPZ-GIFSMMMISA-N (2r,3r,6s)-3-[[(3s)-3-amino-5-[carbamimidoyl(methyl)amino]pentanoyl]amino]-6-(4-amino-2-oxopyrimidin-1-yl)-3,6-dihydro-2h-pyran-2-carboxylic acid Chemical compound O1[C@@H](C(O)=O)[C@H](NC(=O)C[C@@H](N)CCN(C)C(N)=N)C=C[C@H]1N1C(=O)N=C(N)C=C1 CXNPLSGKWMLZPZ-GIFSMMMISA-N 0.000 description 1
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- WHHZSVQZOFCFHL-UHFFFAOYSA-N 3-hydroxypyrrolidine-2,5-dione;sodium Chemical compound [Na].OC1CC(=O)NC1=O WHHZSVQZOFCFHL-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 1
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 1
- 102100036826 Aldehyde oxidase Human genes 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241001465318 Aspergillus terreus Species 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- YXQDRIRSAHTJKM-IMJSIDKUSA-N Cys-Ser Chemical compound SC[C@H](N)C(=O)N[C@@H](CO)C(O)=O YXQDRIRSAHTJKM-IMJSIDKUSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 101710147220 Ent-copalyl diphosphate synthase, chloroplastic Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 101150094690 GAL1 gene Proteins 0.000 description 1
- 102100028501 Galanin peptides Human genes 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 1
- 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 1
- 101100121078 Homo sapiens GAL gene Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 108091022912 Mannose-6-Phosphate Isomerase Proteins 0.000 description 1
- 102000048193 Mannose-6-phosphate isomerases Human genes 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101100261636 Methanothermobacter marburgensis (strain ATCC BAA-927 / DSM 2133 / JCM 14651 / NBRC 100331 / OCM 82 / Marburg) trpB2 gene Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229940122060 Ornithine decarboxylase inhibitor Drugs 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101100124346 Photorhabdus laumondii subsp. laumondii (strain DSM 15139 / CIP 105565 / TT01) hisCD gene Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000206607 Porphyra umbilicalis Species 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000034254 Squamous cell carcinoma of the cervix uteri Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229940127174 UCHT1 Drugs 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- CXNPLSGKWMLZPZ-UHFFFAOYSA-N blasticidin-S Natural products O1C(C(O)=O)C(NC(=O)CC(N)CCN(C)C(N)=N)C=CC1N1C(=O)N=C(N)C=C1 CXNPLSGKWMLZPZ-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002409 epiglottis Anatomy 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 230000008378 epithelial damage Effects 0.000 description 1
- 230000008508 epithelial proliferation Effects 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000198 fluorescence anisotropy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000002980 germ line cell Anatomy 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 101150113423 hisD gene Proteins 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000021158 homophilic cell adhesion Effects 0.000 description 1
- 238000007849 hot-start PCR Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000000111 isothermal titration calorimetry Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000002818 ornithine decarboxylase inhibitor Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000037048 polymerization activity Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 101150081616 trpB gene Proteins 0.000 description 1
- 101150111232 trpB-1 gene Proteins 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03012134.7 | 2003-05-31 | ||
| EP03012134 | 2003-05-31 | ||
| EP03012133.9 | 2003-05-31 | ||
| EP03012133 | 2003-05-31 | ||
| PCT/EP2004/005687 WO2004106383A1 (en) | 2003-05-31 | 2004-05-26 | Pharmaceutical composition comprising a bispecific antibody for epcam |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007530435A JP2007530435A (ja) | 2007-11-01 |
| JP2007530435A5 JP2007530435A5 (enExample) | 2011-02-03 |
| JP5010281B2 true JP5010281B2 (ja) | 2012-08-29 |
Family
ID=33492142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006529930A Expired - Lifetime JP5010281B2 (ja) | 2003-05-31 | 2004-05-26 | Ｅｐｃａｍに対する二重特異性抗体を含む薬学的組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7919089B2 (enExample) |
| EP (1) | EP1629013B1 (enExample) |
| JP (1) | JP5010281B2 (enExample) |
| KR (1) | KR20060015602A (enExample) |
| AU (1) | AU2004242847B2 (enExample) |
| BR (1) | BRPI0410338A (enExample) |
| CA (1) | CA2522894C (enExample) |
| NZ (1) | NZ543202A (enExample) |
| RU (1) | RU2005137325A (enExample) |
| WO (1) | WO2004106383A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8513417B2 (en) | 2007-01-31 | 2013-08-20 | Kyushu University, National University Corporation | Method for synthesis of nitroxyl radical |
Families Citing this family (144)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6358588A (ja) * | 1986-08-29 | 1988-03-14 | Toshiba Corp | バ−コ−ド読取装置 |
| US7906102B2 (en) | 2001-10-03 | 2011-03-15 | Vanderbilt University | Ligands to radiation-induced molecules |
| US7306925B2 (en) | 2001-11-09 | 2007-12-11 | Vanderbilt University | Phage antibodies to radiation-inducible neoantigens |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| KR20060131892A (ko) | 2004-02-16 | 2006-12-20 | 마이크로메트 에이지 | 덜 면역원성인 결합 분자 |
| GB0510790D0 (en) | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| CA2652434A1 (en) | 2005-07-08 | 2007-01-18 | Xencor, Inc. | Optimized proteins that target ep-cam |
| DK1940881T3 (en) * | 2005-10-11 | 2017-02-20 | Amgen Res Munich Gmbh | COMPOSITIONS WITH ARTICLE CROSS-SPECIFIC ANTIBODIES AND APPLICATIONS THEREOF |
| JP2009521474A (ja) * | 2005-12-21 | 2009-06-04 | メディミューン，エルエルシー | ＥｐｈＡ２ＢｉＴＥ分子およびその使用 |
| HUE040467T2 (hu) * | 2007-04-03 | 2019-03-28 | Amgen Res Munich Gmbh | Keresztfaj-specifikus kötõdomén |
| FI2155783T4 (fi) * | 2007-04-03 | 2022-12-15 | Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni | |
| ES2390243T3 (es) * | 2007-04-03 | 2012-11-07 | Amgen Research (Munich) Gmbh | Agentes de unión biespecíficos específicos de especies cruzadas |
| PT3211005T (pt) | 2008-07-08 | 2021-06-15 | Geneuro Sa | Utilização terapêutica de ligandos específicos nas doenças associadas a msrv |
| US20120034228A1 (en) * | 2008-10-01 | 2012-02-09 | Micromet Ag | CROSS-SPECIES-SPECIFIC PSCAxCD3, CD19xCD3, C-METxCD3, ENDOSIALINxCD3, EPCAMxCD3, IGF-1RxCD3 OR FAPALPHAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| TW201125583A (en) * | 2009-12-23 | 2011-08-01 | Bioalliance Cv | Anti-EpCAM antibodies that induce apoptosis of cancer cells and methods using same |
| EP3029066B1 (en) | 2010-07-29 | 2019-02-20 | Xencor, Inc. | Antibodies with modified isoelectric points |
| US20130273055A1 (en) * | 2010-11-16 | 2013-10-17 | Eric Borges | Agents and methods for treating diseases that correlate with bcma expression |
| SG195072A1 (en) | 2011-05-21 | 2013-12-30 | Macrogenics Inc | Cd3-binding molecules capable of binding to human and non-human cd3 |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| WO2013019730A1 (en) | 2011-07-29 | 2013-02-07 | The Washington University | Antibodies to tip-1 and grp78 |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| TWI679212B (zh) * | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| CN102492038B (zh) * | 2011-12-09 | 2014-05-28 | 中国人民解放军军事医学科学院基础医学研究所 | 抗人Tim-3的中和性单克隆抗体L3D及其用途 |
| WO2013083809A1 (en) | 2011-12-09 | 2013-06-13 | Amgen Research (Munich) Gmbh | Prevention of adverse effects caused by epcamxcd3 bispecific antibodies |
| AU2012362378B2 (en) * | 2011-12-27 | 2016-06-23 | Dcb-Usa Llc | Light chain-bridged bispecific antibody |
| EP3786183A3 (en) * | 2012-06-15 | 2021-06-09 | Imaginab, Inc. | Antigen binding constructs to cd3 |
| US20140004121A1 (en) | 2012-06-27 | 2014-01-02 | Amgen Inc. | Anti-mesothelin binding proteins |
| ES2702315T3 (es) | 2012-08-24 | 2019-02-28 | Univ California | Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| US10093736B2 (en) * | 2012-11-13 | 2018-10-09 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
| US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| CA2898100C (en) | 2013-01-14 | 2023-10-10 | Xencor, Inc. | Novel heterodimeric proteins |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| WO2014113510A1 (en) | 2013-01-15 | 2014-07-24 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
| EP2762496A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Method for the selection of antibodies against BCMA |
| JP2016507523A (ja) | 2013-02-05 | 2016-03-10 | エンクマフ アーゲー | ＣＤ３εおよびＢＣＭＡに対する二重特異的抗体 |
| WO2014159531A1 (en) * | 2013-03-14 | 2014-10-02 | The Board Of Regents Of The University Of Texas System | Monoclonal antibodies targeting epcam for detection of prostate cancer lymph node metastases |
| US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
| US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| EP3421495A3 (en) | 2013-03-15 | 2019-05-15 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| CN104342453A (zh) * | 2013-08-06 | 2015-02-11 | 深圳先进技术研究院 | 含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用 |
| CN105813654B (zh) | 2013-10-11 | 2019-05-31 | 美国政府(由卫生和人类服务部的部长所代表) | Tem8抗体及其用途 |
| WO2015103549A1 (en) | 2014-01-03 | 2015-07-09 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| MX385936B (es) | 2014-03-28 | 2025-03-11 | Xencor Inc | Anticuerpos biespecíficos que se unen a cd38 y cd3. |
| US10449261B2 (en) | 2014-07-24 | 2019-10-22 | Washington University | Compositions targeting radiation-induced molecules and methods of use thereof |
| WO2016077789A1 (en) | 2014-11-14 | 2016-05-19 | The Usa, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
| EP3699198B1 (en) | 2014-11-17 | 2025-03-26 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using cd3xcd20 bispecific antibody |
| HRP20211273T1 (hr) | 2014-11-26 | 2021-11-12 | Xencor, Inc. | Heterodimerna protutijela koja vežu cd3 i cd20 |
| MX2017006918A (es) | 2014-11-26 | 2018-01-25 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y cd38. |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| EP3237449A2 (en) | 2014-12-22 | 2017-11-01 | Xencor, Inc. | Trispecific antibodies |
| KR102790523B1 (ko) | 2015-02-24 | 2025-04-02 | 바이오아트라, 인코퍼레이티드 | 조건부 활성 생체 단백질 |
| EP3261665A1 (en) | 2015-02-24 | 2018-01-03 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use |
| WO2016141387A1 (en) | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| HRP20200583T1 (hr) | 2015-03-20 | 2020-07-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Protutijela koja neutraliziraju gp120 i njihova upotreba |
| US11098131B2 (en) | 2015-07-31 | 2021-08-24 | Sutro Biopharma, Inc. | Anti-EpCAM antibodies, compositions comprising anti-EpCAM antibodies and methods of making and using anti-EpCAM antibodies |
| NZ739721A (en) | 2015-08-07 | 2019-09-27 | Imaginab Inc | Antigen binding constructs to target molecules |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| US10392441B2 (en) | 2015-10-07 | 2019-08-27 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia |
| CA3003878A1 (en) | 2015-11-03 | 2017-05-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 gp41 and their use |
| JP7058219B2 (ja) | 2015-12-07 | 2022-04-21 | ゼンコア インコーポレイテッド | Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体 |
| WO2017192589A1 (en) | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
| FI3468586T3 (fi) | 2016-06-14 | 2024-10-29 | Xencor Inc | Bispesifisiä immuuniaktivaatiota vapauttavia vasta-aineita |
| KR20190053835A (ko) | 2016-06-21 | 2019-05-20 | 테네오바이오, 인코포레이티드 | Cd3 결합 항체 |
| MX2018016330A (es) | 2016-06-27 | 2020-02-17 | Univ California | Combinaciones para tratamiento del cáncer. |
| EP3475304B1 (en) | 2016-06-28 | 2022-03-23 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
| AU2017301826A1 (en) | 2016-07-26 | 2019-03-14 | Tessa Therapeutics Ltd. | Chimeric antigen receptor |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| TW201825674A (zh) * | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | 表現雙特異性接合分子的溶瘤病毒 |
| CN114395048B (zh) | 2016-09-14 | 2025-01-28 | 特纳奥尼股份有限公司 | Cd3结合抗体 |
| EP3519436A4 (en) * | 2016-09-30 | 2020-09-09 | Baylor College of Medicine | TISSUE-ORIENTED ANTIBODY-BASED GENE THERAPY |
| CN106632681B (zh) * | 2016-10-11 | 2017-11-14 | 北京东方百泰生物科技有限公司 | 抗egfr和抗cd3双特异抗体及其应用 |
| CA3040504A1 (en) | 2016-10-14 | 2018-04-19 | Xencor, Inc. | Il15/il15ra heterodimeric fc-fusion proteins |
| CN116284402A (zh) | 2016-12-21 | 2023-06-23 | 特尼奥生物股份有限公司 | 仅有重链的抗bcma抗体 |
| US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
| US11352436B2 (en) | 2017-02-10 | 2022-06-07 | Washington University | Antibodies to TIP1 and methods of use thereof |
| US11021535B2 (en) | 2017-02-10 | 2021-06-01 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
| KR102742528B1 (ko) | 2017-06-20 | 2024-12-16 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
| MA49517A (fr) | 2017-06-30 | 2020-05-06 | Xencor Inc | Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| WO2019094637A1 (en) | 2017-11-08 | 2019-05-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
| KR102722731B1 (ko) | 2017-12-19 | 2024-10-25 | 젠코어 인코포레이티드 | 조작된 il-2 fc 융합 단백질 |
| EP3724223A1 (en) | 2018-01-02 | 2020-10-21 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
| WO2019165122A1 (en) | 2018-02-21 | 2019-08-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
| CN112469477A (zh) | 2018-04-04 | 2021-03-09 | Xencor股份有限公司 | 与成纤维细胞活化蛋白结合的异源二聚体抗体 |
| CN108503714A (zh) * | 2018-04-10 | 2018-09-07 | 浙江科途医学科技有限公司 | 一种人白介素2和抗人上皮细胞黏附分子单链抗体融合蛋白及其应用 |
| CA3097741A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
| JP2021521784A (ja) | 2018-04-18 | 2021-08-30 | ゼンコア インコーポレイテッド | ＩＬ−１５／ＩＬ−１５ＲａＦｃ融合タンパク質とＰＤ−１抗原結合ドメインを含むＰＤ−１標的化ヘテロダイマー融合タンパク質およびそれらの使用 |
| JP7398396B2 (ja) | 2018-06-01 | 2023-12-14 | ノバルティス アーゲー | Ｂｃｍａに対する結合分子及びその使用 |
| DK3844189T3 (da) | 2018-08-31 | 2025-02-24 | Regeneron Pharma | Doseringsstrategi, der mindsker cytokinfrigivelsessyndrom for CD3/CD20-bispecifikke antistoffer |
| SG11202103192RA (en) | 2018-10-03 | 2021-04-29 | Xencor Inc | Il-12 heterodimeric fc-fusion proteins |
| WO2020132214A2 (en) | 2018-12-20 | 2020-06-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof |
| MX2021010390A (es) | 2019-03-01 | 2021-11-17 | Xencor Inc | Anticuerpos heterodimericos que se unen a enpp3 y cd3. |
| MX2021012205A (es) | 2019-04-05 | 2022-02-21 | Teneobio Inc | Anticuerpos de cadena pesada que se unen al psma. |
| US12269872B2 (en) | 2019-05-03 | 2025-04-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to Plasmodium falciparum circumsporozoite protein and their use |
| KR20230031981A (ko) | 2019-05-14 | 2023-03-07 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| EP3972998A1 (en) | 2019-05-21 | 2022-03-30 | Novartis AG | Cd19 binding molecules and uses thereof |
| US20230085439A1 (en) | 2019-05-21 | 2023-03-16 | University Of Georgia Research Foundation, Inc. | Antibodies that bind human metapneumovirus fusion protein and their use |
| JP7665538B2 (ja) | 2019-06-14 | 2025-04-21 | テネオバイオ， インコーポレイテッド | Ｃｄ２２及びｃｄ３に結合する多重特異性重鎖抗体 |
| KR20220031054A (ko) | 2019-07-02 | 2022-03-11 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Egfrviii에 결합하는 단일클론 항체 및 이의 용도 |
| GB201912681D0 (en) * | 2019-09-04 | 2019-10-16 | Eth Zuerich | Bispecific binding agent that binds to cd117/c-kit and cd3 |
| US20230046834A1 (en) * | 2019-11-21 | 2023-02-16 | Brown University | Bispecific antibodies against chi3l1 and ctla4 with enhanced cytotoxic effects on tumor cells |
| EP4186564A1 (en) | 2020-04-29 | 2023-05-31 | Teneoone, Inc. | Multispecific heavy chain antibodies with modified heavy chain constant regions |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| WO2022040482A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| WO2022072291A1 (en) * | 2020-09-30 | 2022-04-07 | Amgen Inc. | Cation exchange chromatography process |
| WO2022132904A1 (en) | 2020-12-17 | 2022-06-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies targeting sars-cov-2 |
| AU2021414400A1 (en) | 2020-12-31 | 2023-08-17 | Innate Pharma | Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123 |
| WO2022161314A1 (zh) | 2021-01-27 | 2022-08-04 | 信达生物制药(苏州)有限公司 | 针对cd16a的单域抗体及其用途 |
| JP2024506315A (ja) | 2021-02-09 | 2024-02-13 | ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ | コロナウイルスのスパイクタンパク質を標的とする抗体 |
| WO2022173689A1 (en) | 2021-02-09 | 2022-08-18 | University Of Georgia Research Foundation, Inc. | Human monoclonal antibodies against pneumococcal antigens |
| CN117157319A (zh) | 2021-03-09 | 2023-12-01 | Xencor股份有限公司 | 结合cd3和cldn6的异二聚抗体 |
| KR20230154311A (ko) | 2021-03-10 | 2023-11-07 | 젠코어 인코포레이티드 | Cd3 및 gpc3에 결합하는 이종이량체 항체 |
| EP4355778A1 (en) | 2021-06-17 | 2024-04-24 | Boehringer Ingelheim International GmbH | Novel tri-specific binding molecules |
| CA3232223A1 (en) | 2021-09-17 | 2023-03-23 | Ying Fu | Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies |
| AU2021474386A1 (en) * | 2021-11-19 | 2024-06-27 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody and use thereof |
| WO2023151620A1 (zh) * | 2022-02-09 | 2023-08-17 | 恺兴生命科技(上海)有限公司 | 用于细胞免疫学的组合物和方法 |
| CN118984836A (zh) | 2022-02-10 | 2024-11-19 | 美国政府(由卫生和人类服务部的部长所代表) | 广泛靶向冠状病毒的人单克隆抗体 |
| EP4499228A1 (en) | 2022-03-28 | 2025-02-05 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to hiv-1 env and their use |
| AU2023274452A1 (en) | 2022-05-27 | 2025-01-16 | Innate Pharma | Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering |
| EP4565329A1 (en) | 2022-08-01 | 2025-06-11 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Monoclonal antibodies that bind to the underside of influenza viral neuraminidase |
| WO2024054822A1 (en) | 2022-09-07 | 2024-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Engineered sars-cov-2 antibodies with increased neutralization breadth |
| WO2024064826A1 (en) | 2022-09-22 | 2024-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
| WO2024082269A1 (zh) * | 2022-10-21 | 2024-04-25 | 武汉友芝友生物制药股份有限公司 | 双特异性抗体在免疫细胞治疗方面的应用 |
| EP4638491A1 (en) | 2022-12-19 | 2025-10-29 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Monoclonal antibodies for treating sars-cov-2 infection |
| WO2024138155A1 (en) | 2022-12-22 | 2024-06-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ebolavirus (sudan and zaire) antibodies from non-human primates and human vaccinees |
| WO2024226646A2 (en) * | 2023-04-25 | 2024-10-31 | Memorial Sloan-Kettering Cancer Center | Dlk1 -targeting antibodies and uses thereof |
| WO2024243355A1 (en) | 2023-05-24 | 2024-11-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that target the rh5 complex of blood-stage plasmodium falciparum |
| WO2025014896A1 (en) | 2023-07-07 | 2025-01-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Humanized 40h3 antibody |
| WO2025024233A1 (en) | 2023-07-21 | 2025-01-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bispecific antibodies that broadly target coronaviruses |
| WO2025106427A1 (en) | 2023-11-14 | 2025-05-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv) |
| WO2025117384A1 (en) | 2023-12-01 | 2025-06-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Broadly neutralizing influenza hemagglutinin stem-directed antibodies |
| WO2025137284A2 (en) | 2023-12-21 | 2025-06-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Broadly neutralizing antibodies against sars-cov-2 and sars-cov variants |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19531348A1 (de) | 1995-08-25 | 1997-02-27 | Gsf Forschungszentrum Umwelt | Antikörper mit zwei oder mehr Spezifitäten zur selektiven Eliminierung von Zellen in vivo |
| US7435549B1 (en) * | 1997-11-17 | 2008-10-14 | Micromet Ag | Method of identifying binding site domains that retain the capacity of binding to an epitope |
| ID28117A (id) * | 1998-07-10 | 2001-05-03 | Connex Gmbh | Reagen imunologi yang secara khusus berinteraksi dengan domain ekstraseluler pada rantai zeta manusia |
| DK1100830T3 (da) * | 1998-07-28 | 2004-01-19 | Micromet Ag | Heterominiantistoffer |
| IT1301968B1 (it) | 1998-07-30 | 2000-07-20 | Zambon Spa | Derivati di eritromicina ad attivita' antibiotica |
| IL151873A0 (en) * | 2000-03-24 | 2003-04-10 | Micromet Ag | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
-
2004
- 2004-05-26 KR KR1020057021529A patent/KR20060015602A/ko not_active Withdrawn
- 2004-05-26 WO PCT/EP2004/005687 patent/WO2004106383A1/en not_active Ceased
- 2004-05-26 JP JP2006529930A patent/JP5010281B2/ja not_active Expired - Lifetime
- 2004-05-26 RU RU2005137325/13A patent/RU2005137325A/ru not_active Application Discontinuation
- 2004-05-26 CA CA2522894A patent/CA2522894C/en not_active Expired - Lifetime
- 2004-05-26 AU AU2004242847A patent/AU2004242847B2/en not_active Expired
- 2004-05-26 BR BRPI0410338-6A patent/BRPI0410338A/pt not_active IP Right Cessation
- 2004-05-26 NZ NZ543202A patent/NZ543202A/en not_active IP Right Cessation
- 2004-05-26 EP EP04734816.4A patent/EP1629013B1/en not_active Expired - Lifetime
- 2004-05-26 US US10/554,851 patent/US7919089B2/en active Active
-
2011
- 2011-04-04 US US13/079,453 patent/US8790645B2/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8513417B2 (en) | 2007-01-31 | 2013-08-20 | Kyushu University, National University Corporation | Method for synthesis of nitroxyl radical |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20060015602A (ko) | 2006-02-17 |
| CA2522894A1 (en) | 2004-12-09 |
| US20070081993A1 (en) | 2007-04-12 |
| US8790645B2 (en) | 2014-07-29 |
| AU2004242847A1 (en) | 2004-12-09 |
| EP1629013A1 (en) | 2006-03-01 |
| NZ543202A (en) | 2008-04-30 |
| RU2005137325A (ru) | 2006-09-10 |
| US20110256137A1 (en) | 2011-10-20 |
| BRPI0410338A (pt) | 2006-05-30 |
| EP1629013B1 (en) | 2018-01-24 |
| JP2007530435A (ja) | 2007-11-01 |
| US7919089B2 (en) | 2011-04-05 |
| AU2004242847B2 (en) | 2011-06-09 |
| WO2004106383A1 (en) | 2004-12-09 |
| CA2522894C (en) | 2013-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5010281B2 (ja) | Ｅｐｃａｍに対する二重特異性抗体を含む薬学的組成物 | |
| JP7273106B2 (ja) | 異種間特異的ｐｓｍａ×ｃｄ３二重特異性単鎖抗体 | |
| JP6025502B2 (ja) | Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物 | |
| JP4948174B2 (ja) | 多重特異的脱免疫ｃｄ３−結合物質 | |
| EP1716178B1 (en) | Less immunogenic binding molecules | |
| JP2023542900A (ja) | ４－１ｂｂを標的とする単一ドメイン抗体、その融合タンパク質、その医薬組成物及び使用 | |
| ZA200508279B (en) | Pharmaceutical composition comprising a bispecific antibody for epcam | |
| HK1086846B (en) | Multispecific deimmunized cd3-binders | |
| HK1149281A (en) | Multispecific deimmunized cd3-binders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100610 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100909 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100916 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101210 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20101210 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110404 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110803 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110805 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110927 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20110930 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111130 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120216 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120223 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120316 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120528 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120601 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5010281 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150608 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150608 Year of fee payment: 3 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150608 Year of fee payment: 3 |
|
| R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150608 Year of fee payment: 3 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150608 Year of fee payment: 3 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
| R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |